NEW YORK, October 5, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com reviews the following Biotech equities: Peregrine Pharmaceuticals Inc.
(NASDAQ: PPHM), PTC Therapeutics Inc. (NASDAQ: PTCT), Aratana Therapeutics Inc. (NASDAQ: PETX), and Vanda Pharmaceuticals Inc.
(NASDAQ: VNDA). According to a new report by Grand View Research, the global white biotechnology market is expected to grow at a
CAGR of 10.2% from 2016 to 2024, while the biofuels segment is forecasted to grow at a CAGR of more than 9% over the same period.
Download the free research reports on these stocks today:
http://stock-callers.com/registration
Peregrine Pharma
Tustin, California headquartered Peregrine Pharmaceuticals Inc.'s stock finished Tuesday's
session 2.00% lower at $0.43. A total volume of 1.36 million shares was traded, which was above
their three months average volume of 1.06 million shares. The Company's shares have advanced 12.18% in the past month and 12.18%
in the previous three months. The stock is trading 11.57% above its 50-day moving average. Additionally, shares of Peregrine
Pharmaceuticals, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have a Relative
Strength Index (RSI) of 61.46.
On September 27th, 2016, Peregrine Pharmaceuticals announced the presentation of
preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance
the anti-tumor activity of multiple checkpoint targeting agents including anti-PD-1 and anti-LAG3 therapies in a model of triple
negative breast cancer (TNBC). Data showed that eight of the ten (80%) animals receiving the preclinical bavituximab equivalent
(ch1N11) combined with anti-PD-1 and anti-LAG3 therapies ("Triple Combination") experienced complete tumor regressions, whereas
there were no animals (0/10) in the anti-PD-1 and anti-LAG3 combination treatment arm that had a complete regression. See our
free and comprehensive research report on PPHM at:
http://stock-callers.com/registration/?symbol=PPHM
PTC Therapeutics
On Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc.
recorded a trading volume of 1.14 million shares. The stock ended the session 0.22% lower at $13.33. The Company's shares have surged 68.52% in the last one month and 87.48% over the previous three
months. The stock is trading 56.53% above its 50-day moving average and 11.62% above its 200-day moving average. Moreover, shares
of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule
drugs that target post-transcriptional control processes, have an RSI of 73.83.
On October 4th, 2016, PTC Therapeutics announced that the Proceedings of the National
Academy of Sciences (PNAS) has published new results further validating Translarna's™ (ataluren) mechanism of action to promote
readthrough of premature stop codons resulting from nonsense mutations in genetic disorders. The results reported in PNAS
establish ataluren's ability to alter the protein production process at premature stop codons and to promote the insertion of
specific amino acids and restore the production of a full-length functional protein. PTCT free research report PDF is just a
click away at:
http://stock-callers.com/registration/?symbol=PTCT
Aratana Therapeutics
Shares in Leawood, Kansas headquartered Aratana Therapeutics Inc. closed the day 0.87% lower
at $10.30. The stock recorded a trading volume of 1.08 million shares, which was higher than its
three months average volume of 757,120 shares. The Company's shares have gained 16.91% in the last month, 56.53% in the previous
three months, and 84.59% on an YTD basis. The stock is trading 16.70% above its 50-day moving average and 65.73% above its
200-day moving average. Additionally, shares of Aratana Therapeutics, which focuses on the licensing, development, and
commercialization of biopharmaceutical products for the companion animals worldwide, have an RSI of 64.42.
As per notes filed with the SEC on September 01st, 2016, Julia Stephanus provided Aratana Therapeutics on July 30th, 2016,
with a notice to cure and contingent resignation of her employment agreement. On August
30th, 2016, Ms. Stephanus and the Company entered into a consulting and separation agreement, which provides
for her continued employment as Chief Commercial Officer of the Company until September
30th, 2016 following which she agreed to serve as a commercial consultant to the Company.
On September 6th, 2016, research firm Lake Street resumed its 'Buy' rating on the
Company's stock, issuing a target price of $15 per share. Sign up for your complimentary report on
PETX at:
http://stock-callers.com/registration/?symbol=PETX
Vanda Pharma
At the close, shares in Washington, the District of Columbia
headquartered Vanda Pharmaceuticals Inc. ended the day at $16.23, which was a slight decline of
0.79%. The stock recorded a trading volume of 459,400 shares. The Company's shares have advanced 4.37% in the last one month,
39.31% in the previous three months, and 74.33% since the start of this year. The stock is trading above its 50-day and 200-day
moving averages by 14.69% and 55.06%, respectively. Furthermore, shares of Vanda Pharmaceuticals, which focuses on the
development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 56.80.
Register for free on Stock-Callers.com and download the latest research report on VNDA at:
http://stock-callers.com/registration/?symbol=VNDA
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA